Clinical Trials Directory

Trials / Unknown

UnknownNCT02892851

Deep Brain Stimulation of the Sub-Thalamic Nucleus to Treat Severe and Treatment-resistant Cocaine Addiction.

A Pilot Study of Deep Brain Stimulation of the Sub-thalamic Nucleus to Treat Treatment-resistant Cocaine Addiction With Severe Somatic or Psychiatric Complications

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
2 (estimated)
Sponsor
Assistance Publique - Hôpitaux de Paris · Academic / Other
Sex
All
Age
30 Years – 55 Years
Healthy volunteers
Not accepted

Summary

Cocaine addiction is a chronic condition with severe cardiac, neurologic, psychiatric and social complications. Cocaine is the second most consumed illicit drug in France. Its prevalence has been multiplied by 3 between 2000 and 2008, and is still on the rise. Craving, the compulsive need to consume, is a key feature of cocaine addiction. It is also predictive of treatment efficacy. However, there is no validated treatment for severe cocaine dependence yet. Response to current psychological and medical treatment is poor, with 73% relapse after 3 months. Patients with severe cocaine addiction are thus in a therapeutic deadlock. To address these unmet medical needs, the investigators designed a pilot study (n=2) to evaluate the safety and the efficacy of the deep brain stimulation of the subthalamic nuclei (STN-DBS) in severe cocaine addiction with at least one cardiac, neurologic or psychiatric complication. Indeed, compulsivity is a critical component of craving, and severe treatment-resistant obsessive compulsive disorder (OCD) are already successfully treated using STN-DBS. Moreover, animal studies recently demonstrated a therapeutic effect of STN-DBS in rats addicted to cocaine. Together, these two lines of research suggest a therapeutic effect of STN-DBS in cocaine addiction mediated by an anti-obsessive mechanism on craving.

Conditions

Interventions

TypeNameDescription
DEVICEDeep brain stimulation of the subthalamic nuclei (STN-DBS)3 phases : * Parameter setting * Cross-over double-bind (ON/OFF) * Open Phase (ON)

Timeline

Start date
2014-03-01
Primary completion
2017-09-01
Completion
2018-03-01
First posted
2016-09-08
Last updated
2016-09-08

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT02892851. Inclusion in this directory is not an endorsement.